ReviewCurrent allergy and asthma reports2011
Severe asthma with fungal sensitization.
Review in Current allergy and asthma reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33.The Journal of allergy and clinical immunology · 2015Trial
- Systemic azoles for asthma with fungal sensitisation.The Cochrane database of systematic reviews · 2026Article
- Fungal exposure exacerbates allergen-driven asthma in a two-hit mouse model.Respiratory research · 2026Article
- Eosinophil-Derived Neurotoxin: A Potential Biomarker for Allergic Bronchopulmonary Aspergillosis.Journal of asthma and allergy · 2026Article
- Allergic Fungal Rhinosinusitis Diagnosis, Management, Associated Conditions, Pathophysiology, and Future Directions: Summary of a Multidisciplinary Workshop.International forum of allergy & rhinology · 2025Review
- Proposal and Verification of New Revised Criteria for ABPA/ABPM Diagnosis.Journal of asthma and allergy · 2025Article
- Moving beyond species: fungal function in house dust provides novel targets for potential indicators of mold growth in homes.Microbiome · 2024Article
- Article
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
- Aspergillus Sensitization and Allergic Bronchopulmonary Aspergillosis in Asthmatic Children: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2023Review
- RAGE contributes to allergen driven severe neutrophilic airway inflammationFrontiers in immunology · 2023Article
- Fungal-mediated lung allergic airway disease: The critical role of macrophages and dendritic cells.PLoS pathogens · 2022Review
- Occurrence of Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations in Patients with Allergic Bronchopulmonary Aspergillosis Complicating Asthma.Mycopathologia · 2022Article
- Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent.Children (Basel, Switzerland) · 2022Article
- The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children.The journal of allergy and clinical immunology. In practice · 2022Article
- Therapeutic Approaches for CombatingCurrent drug targets · 2022Review
- Allergic Bronchopulmonary Aspergillosis with an Atypical Mass-Like Presentation.Case reports in pulmonology · 2022Article
- Identification of key genes in allergic rhinitis by bioinformatics analysis.The Journal of international medical research · 2021Article
- Novel Mouse Models of Fungal Asthma.Frontiers in cellular and infection microbiology · 2021Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new phenotype of asthma has been described recently, namely severe asthma with fungal sensitization (SAFS). SAFS can be conceptualized as a continuum of fungal sensitization, with asthma at one end and allergic bronchopulmonary aspergillosis at the other. It is diagnosed by the presence of severe asthma, fungal sensitization, and exclusion of allergic bronchopulmonary aspergillosis. Because of the paucity of data and ambiguity in diagnostic criteria, SAFS is currently more of a diagnosis of exclusion than a specific entity. Treatment of SAFS initially should be similar to that of severe asthma, including the use of omalizumab. The potential role of itraconazole as a specific therapy in SAFS requires more evidence before it can be incorporated in routine practice. An urgent need exists for data regarding the prevalence, natural history, and clinical relevance of SAFS so that its exact characterization and importance as a specific subtype of asthma can be clearly defined. This review summarizes the current understanding of the pathogenesis, diagnosis, and management of SAFS.
Indexed as
Identifiers
21789577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.